拓新药业(301089.SZ)：上半年净亏损1828万元

Group 1 - The core viewpoint of the article highlights that Tuoxin Pharmaceutical (301089.SZ) has experienced significant pressure in its operating performance for the first half of 2025, with a notable decline in revenue and net profit [1] Group 2 - The company reported an operating revenue of 180 million yuan, representing a year-on-year decrease of 16.85% [1] - The net profit attributable to shareholders of the listed company was -18.28 million yuan, reflecting a staggering year-on-year decline of 927.39% [1]